Patients with moderate to severe chronic spontaneous urticaria that were antihistamine-resistant to omalizumab experienced ...

CHRONIC spontaneous urticaria (CSU) is a distressing inflammatory skin condition characterised by the recurrent appearance of ...

A new study published in the Journal of American Medical Association showed that Rilzabrutinib decreased itching and hives ...

SNY's Rilzabrutinib Under Review for Immune Thrombocytopenia Sanofi has developed rilzabrutinib for treating immune thrombocytopenia (“ITP”), another rare, complex autoimmune disorder. A ...

Rilzabrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), demonstrated a rapid and substantial alleviation of symptoms in patients with chronic spontaneous urticaria (CSU) unresponsive to ...

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune ...

Sanofi has chalked up another win in a clinical trial of its oral BTK inhibitor rilzabrutinib, setting up regulatory filings in its first indication – rare disorder immune thrombocytopenia (ITP ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease ...